Blenrep approved in Australia for use in adults with relapsed or refractory multiple myeloma as part of triplet combination therapy

CAR-T Digest - August 2020

Weekly Digest - November 2025

24 November 2025: Blenrep approved in Australia for use in adults with relapsed or refractory multiple myeloma as part of triplet combination therapy

Australia has approved Blenrep (belantamab mafodotin), a first-of-its-kind “Trojan Horse” antibody-drug conjugate, for adults with multiple myeloma who have relapsed or become resistant to first-line therapy, to be used as part of triplet combinations
The approval addresses a significant unmet need in an incurable cancer where relapse is common, supported by extensive evidence from international and australian Phase 3 trials of Blenrep
Clinicians and patient advocates highlight the significance of a treatment that works through a novel mechanism selectively binding to myeloma cells and delivering a targeted cancer-killing agent internally
Blenrep can be combined with existing therapies (bortezomib + dexamethasone or pomalidomide + dexamethasone after lenalidomide), administered via a 30-minute outpatient infusion, but requires careful eye monitoring due to known ocular side effects
The therapy is not yet funded on the Pharmaceutical Benefits Scheme (PBS), though reimbursement is under review, underscoring continued challenges in patient access despite strong clinical need